Heart failure drug proscillaridin A targets MYC overexpressing leukemia through global loss of lysine acetylation

Heart failure drug proscillaridin A targets MYC overexpressing leukemia through global loss of lysine acetylation

Abstract Background Cardiac glycosides are approved for the treatment of heart failure as Na+/K+ pump inhibitors. Their repurposing in oncology is currently investigated in preclinical and clinical studies. However, the identification of a specific cancer type defined by a molecular signature to des...

Full description

Bibliographic Details
Main Authors: Elodie M. Da Costa, Gregory Armaos, Gabrielle McInnes, Annie Beaudry, Gaël Moquin-Beaudry, Virginie Bertrand-Lehouillier, Maxime Caron, Chantal Richer, Pascal St-Onge, Jeffrey R. Johnson, Nevan Krogan, Yuka Sai, Michael Downey, Moutih Rafei, Meaghan Boileau, Kolja Eppert, Ema Flores-Díaz, André Haman, Trang Hoang, Daniel Sinnett, Christian Beauséjour, Serge McGraw, Noël J.-M. Raynal
Format: Article
Language:English
Published: BMC 2019-06-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
Cardiac glycosides
Proscillaridin A
MYC
Leukemia
Lysine acetylation
Chromatin remodelling
Online Access:http://link.springer.com/article/10.1186/s13046-019-1242-8

Internet

http://link.springer.com/article/10.1186/s13046-019-1242-8

Similar Items